How to access Nuplazid from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient with hallucinations or delusions associated with Parkinson's disease psychosis may receive a prescription for Nuplazid (pimavanserin) from their treating neurologist or movement-disorder specialist. Nuplazid is FDA-approved for this indication and developed by Acadia Pharmaceuticals. It is not a controlled substance. In India, Nuplazid is not locally registered, and access is coordinated through the named-patient / personal-use import pathway.
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Nuplazid is an oral selective serotonin 5-HT2A inverse agonist, taken once daily at 34 mg (typically two 17 mg capsules or one 34 mg tablet). Unlike typical or atypical antipsychotics, Nuplazid lacks significant dopamine receptor antagonism, which makes it attractive for Parkinson's patients who cannot tolerate the motor worsening of dopamine-blocking antipsychotics. Eligibility anchors to documented Parkinson's disease, active psychosis symptoms sufficient to warrant treatment, and QT assessment. Nuplazid carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis — your neurologist documents the risk/benefit discussion.
Is Nuplazid legally importable into India?
Yes — through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. The mechanism permits a registered medical practitioner (or the patient on personal-use grounds with physician documentation) to request import of an FDA-approved medicine where no clinically equivalent registered alternative exists. Parkinson's disease psychosis has limited disease-specific registered options in India.
How the pathway works, step by step
- Consultation with your treating neurologist or movement-disorder specialist. Parkinson's diagnosis, psychosis characterisation, and clinical rationale.
- Baseline assessment. QT assessment (ECG), concomitant medication review for QT-prolonging agents, boxed-warning discussion documentation.
- CDSCO personal-use / named-patient application. The physician or hospital files clinical rationale, patient identification, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Nuplazid from authorised distribution under DSCSA.
- Ambient shipment. Nuplazid ships under controlled ambient conditions with chain-of-custody documentation and customs clearance support.
- Arrival and dispensing. The hospital pharmacy or licensed personal-use receiver releases the bottle to the patient.
What documentation your physician needs
- Clinical rationale letter confirming Parkinson's psychosis and Nuplazid as the indicated therapy
- Verification of Indian medical registration (NMC)
- Baseline ECG with QT assessment
- Concomitant-medication review for QT-prolonging agents
- Boxed-warning discussion documentation
- Patient identifier and address for the import record
Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers and Indian customs expect for Parkinson's-related named-patient and personal-use imports.
Costs and timing
Nuplazid's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 40,000–45,000 for continuous daily dosing. International logistics, customs clearance, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted and customs processing begins.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO / customs review.
- Logistics. Ambient-controlled shipment with customs clearance support.
- Concierge case lead. A named point of contact coordinating monthly refills — often helpful where caregiving is distributed across a family and diaspora.
What we do not do: We are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during pre-launch.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. See our trust and compliance page.
Is Nuplazid a controlled substance? No. Pimavanserin is not a scheduled controlled substance.
Why not use quetiapine or another atypical antipsychotic? Many atypical antipsychotics worsen Parkinson's motor symptoms via dopamine antagonism. Nuplazid's mechanism avoids this. Your neurologist selects based on the specific clinical picture.
What is the boxed warning about? Like other antipsychotic-class medicines, Nuplazid carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis. Your neurologist documents the risk/benefit discussion at initiation.
Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider case by case; we supply documentation but do not process claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Nuplazid coordination.
Add me to the Nuplazid waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.